{"resourceType":"PlanDefinition","id":"TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan","meta":{"profile":["https://www.ceosys.de/fhir/StructureDefinition/recommendation-plan"]},"text":{"status":"extensions","div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><p><b>Generated Narrative: PlanDefinition</b><a name=\"TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan\"> </a></p><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Resource PlanDefinition \"TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan\" </p><p style=\"margin-bottom: 0px\">Profile: <a href=\"file:///github/workspace/output/StructureDefinition-recommendation-plan.html\">Recommendation Plan</a></p></div><p><b>knowledgeCapability</b>: computable</p><p><b>knowledgeRepresentationLevel</b>: structured</p><p><b>url</b>: <code>https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/intervention-plan/therapeutic-anticoagulation</code></p><p><b>version</b>: 7.0</p><p><b>name</b>: Therapeutic_Anticoagulation_No_Renal_Function_Impairment</p><p><b>title</b>: Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients)</p><p><b>type</b>: ECA Rule <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"http://build.fhir.org/codesystem-plan-definition-type.html\">PlanDefinitionType</a>#eca-rule)</span></p><p><b>status</b>: active</p><p><b>experimental</b>: true</p><p><b>subject</b>: <a href=\"EvidenceVariable-PopHospitalisedNonICUCOVID19PatientsWOThrombosisWITHHighRisk.html\">COVID19_patients_NOT_ICU_without_venous_thrombosis_with_high_risk</a></p><p><b>date</b>: 2022-02</p><p><b>publisher</b>: NUM CODEX+ CELIDA</p><p><b>description</b>: In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered.</p><blockquote><p><b>goal</b></p><p><b>category</b>: Laboratory test finding (navigational concept) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#118246004)</span></p><p><b>description</b>: aPTT value should be &gt; 50 sec. <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> ()</span></p><h3>Targets</h3><table class=\"grid\"><tr><td>-</td><td><b>Measure</b></td><td><b>Detail[x]</b></td></tr><tr><td>*</td><td>aPTT in Pooled Platelet poor plasma by Coagulation assay <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://loinc.org/\">LOINC</a>#50754-1)</span></td><td>50-? sec</td></tr></table></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: Administration of substance (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#432102000)</span></p><p><b>goalId</b>: aPTT-goal</p><p><b>selectionBehavior</b>: exactly-one</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationUFH.html\">TherapeuticAnticoagulationPlanUFH</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: Administration of substance (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#432102000)</span></p><p><b>selectionBehavior</b>: exactly-one</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHDalteparin.html\">TherapeuticAnticoagulationDalteparinPlan</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: Administration of substance (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#432102000)</span></p><p><b>selectionBehavior</b>: exactly-one</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHEnoxaparin.html\">TherapeuticAnticoagulationPlanEnoxaparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: Administration of substance (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#432102000)</span></p><p><b>selectionBehavior</b>: exactly-one</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHNadroparinLowWeight.html\">TherapeuticAnticoagulationPlanNadroparinLowWeight</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: Administration of substance (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#432102000)</span></p><p><b>selectionBehavior</b>: exactly-one</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHNadroparinHighWeight.html\">TherapeuticAnticoagulationPlanNadroparinHighWeight</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: Administration of substance (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#432102000)</span></p><p><b>selectionBehavior</b>: exactly-one</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationNMHCertoparin.html\">TherapeuticAnticoagulationPlanCertoparin</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: Administration of substance (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#432102000)</span></p><p><b>selectionBehavior</b>: exactly-one</p><p><b>precheckBehavior</b>: no</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationFondaparinux.html\">TherapeuticAnticoagulationPlanFondaparinux</a></p></blockquote><blockquote><p><b>action</b></p><p><b>code</b>: Administration of substance (procedure) <span style=\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"> (<a href=\"https://browser.ihtsdotools.org/\">SNOMED CT</a>#432102000)</span></p><p><b>goalId</b>: aPTT-goal</p><p><b>selectionBehavior</b>: all</p><p><b>definition</b>: <a href=\"ActivityDefinition-TherapeuticAnticoagulationWArgatra.html\">TherapeuticAnticoagulationPlanArgatroban</a></p></blockquote></div>"},"extension":[{"url":"http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability","valueCode":"computable"},{"url":"http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel","valueCode":"structured"}],"url":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/intervention-plan/therapeutic-anticoagulation","version":"7.0","name":"Therapeutic_Anticoagulation_No_Renal_Function_Impairment","title":"Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients)","type":{"coding":[{"system":"http://terminology.hl7.org/CodeSystem/plan-definition-type","code":"eca-rule"}]},"status":"active","experimental":true,"subjectCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/population/hospitalised-non-icu-covid19-patients-no-venous-thrombosis-high-risk","date":"2022-02","publisher":"NUM CODEX+ CELIDA","description":"In hospitalized, non-intensive care patients with COVID-19 and increased risk (e.g., D-dimers ≥ 2 mg/l), therapeutic anticoagulation can be considered if the risk of bleeding is low. Anticoagulation, preferentially with NMH or UFH, can be considered.","goal":[{"id":"aPTT-goal","category":{"coding":[{"system":"http://snomed.info/sct","code":"118246004","display":"Laboratory test finding (navigational concept)"}]},"description":{"text":"aPTT value should be > 50 sec."},"target":[{"measure":{"coding":[{"system":"http://loinc.org","code":"50754-1","display":"aPTT in Pooled Platelet poor plasma by Coagulation assay"}]},"detailRange":{"low":{"value":50,"unit":"sec","system":"http://unitsofmeasure.org","code":"s"}}}]}],"action":[{"code":{"coding":[{"system":"http://snomed.info/sct","code":"432102000","display":"Administration of substance (procedure)"}]},"goalId":["aPTT-goal"],"selectionBehavior":"exactly-one","definitionCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/recommended-action/drug-administration-action/therapeutic-anticoagulant-UFH-administration"},{"code":{"coding":[{"system":"http://snomed.info/sct","code":"432102000","display":"Administration of substance (procedure)"}]},"selectionBehavior":"exactly-one","definitionCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/recommended-action/drug-administration-action/therapeutic-anticoagulant-dalteparin-administration"},{"code":{"coding":[{"system":"http://snomed.info/sct","code":"432102000","display":"Administration of substance (procedure)"}]},"selectionBehavior":"exactly-one","definitionCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/recommended-action/drug-administration-action/therapeutic-anticoagulant-enoxaparin-administration"},{"code":{"coding":[{"system":"http://snomed.info/sct","code":"432102000","display":"Administration of substance (procedure)"}]},"selectionBehavior":"exactly-one","definitionCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/recommended-action/drug-administration-action/therapeutic-anticoagulant-nadroparin-administration-low-weight"},{"code":{"coding":[{"system":"http://snomed.info/sct","code":"432102000","display":"Administration of substance (procedure)"}]},"selectionBehavior":"exactly-one","definitionCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/recommended-action/drug-administration-action/therapeutic-anticoagulant-nadroparin-administration-high-weight"},{"code":{"coding":[{"system":"http://snomed.info/sct","code":"432102000","display":"Administration of substance (procedure)"}]},"selectionBehavior":"exactly-one","definitionCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/recommended-action/drug-administration-action/therapeutic-anticoagulant-certoparin-administration"},{"code":{"coding":[{"system":"http://snomed.info/sct","code":"432102000","display":"Administration of substance (procedure)"}]},"selectionBehavior":"exactly-one","precheckBehavior":"no","definitionCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/recommended-action/drug-administration-action/therapeutic-anticoagulant-fondaparinux-administration"},{"code":{"coding":[{"system":"http://snomed.info/sct","code":"432102000","display":"Administration of substance (procedure)"}]},"goalId":["aPTT-goal"],"selectionBehavior":"all","definitionCanonical":"https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/recommendations/recommended-action/drug-administration-action/therapeutic-anticoagulant-argatroban-administration"}]}